Skip to content

Author

Bowen Li

We have 6 of 79 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access 2026

Toward a lab-in-the-loop AI platform for RNA therapeutics

RNA therapeutics, spanning messenger RNA vaccines, small interfering RNAs, antisense oligonucleotides, and aptamers, are advancing rapidly, yet the design space that governs whether an RNA drug succeeds remains difficult to navigate. Its principal determinants, namely sequence, chemical modification, secondary struct...

Gen Li, Bo-Wen Li · 0 citations
#gene editing Oct 2026

Editing cells in place: Targeted in vivo gene editing of hematopoietic stem cells.

Traditional ex vivo hematopoietic stem cell (HSC) gene therapy faces manufacturing challenges. A recent study1 in Nature Biomedical Engineering demonstrates that antibody-engineered lipid nanoparticles achieve efficient and durable in vivo editing of HSCs in humanized mice, offering a promising therapeutic strategy for...

Sijin Luozhong, A. Varesi, Bo-Wen Li · 0 citations
Review Aug 2026

Lipid Nanoparticles Based Multi-Scale Systemic Immune Programming for Cancer Therapy.

A dual-track therapeutic paradigm that integrates tumor-directed immune activation with host physiological restoration is proposed, which positions LNP-based therapies to treat cancer as a systemic immune-metabolic disorder rather than a localized disease.

Xinwen Lin, Yong Li, Xi-Ling Shen et al. · 0 citations
Aug 2026

Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis.

This work combined site-specific chemical modification of sup-tRNAs with cargo-tailored pulmonary lipid nanoparticle (LNP) engineering to overcome barriers and restore cystic fibrosis transmembrane conductance regulator (CFTR) expression and function.

Jin-Gan Chen, Mu-Ye Zhou, Song-Tao Dong et al. · 2 citations
Aug 2026

Locus-specific transposable element expression drives human hematopoietic stem cell disease pathophysiology

This study provides direct evidence that VEXAS-specific TE govern HSC clonal dominance, thereby uncovering a regulatory axis underlying HSC biology and disease mechanisms, opening a therapeutic strategy directed towards the repetitive genome.

A. Varesi, Sontago Dong, Chiara Gaddoni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.